Exclusive: Mission Bio Partners With LabCorp to Accelerate Targeted Drug Development

Mission Bio与LapCorp合作加速癌症领域靶向药物开发,对中国市场充满兴趣

2019-04-09 09:00:00 BioSpace

本文共1607个字,阅读需5分钟

South San Francisco-based Mission Bio, the only company providing single-cell DNA sequencing, entered into a collaboration with LabCorp, to harness the abilities of the company’s Tapestri Platform to provide more precise clinical trials. North Carolina-based LabCorp has a network of 36 clinical laboratories across the United States. Also, as part of the deal, LabCorp will evaluate the Tapestri Platform for applications in clinical diagnostics and in the development of new companion diagnostics. Last year the company supported Mission Bio’s $30 million Series B funding round. Charlie Silver, Mission Bio’s chief executive officer, said the partnership with LabCorp is a way for his company to expand its reach and allow them to provide greater service to their customers. Silver told BioSpace in an exclusive interview, that LabCorp’s use of the Tapestri Platform will not only expand Mission Bio’s reach with pharma companies that use LabCorp, but will likely lead to interest from those pharma companies into using the Tapestri Platform in their clinical trial processes as a way to improve them. Silver said the partnership and their platform will help those companies accelerate drug development, particularly in the areas of cancer. Multiple cancer researchers, particularly those working with blood cancers, have turned to using the Tapestri Platform, Silver said. Since the product launched in 2017, blood cancers have been a particular area of focus for the company. The genomics of blood cancer is fairly well-understood, Silver said, and there are more drugs coming to market based on genomic pathways. Silver noted that the U.S. Food and Drug Administration is beginning to look at biomarkers for blood cancers and is expected to issue a new draft guidance soon. A focus on the biomarkers will likely benefit Mission Bio because of its single cell analysis platform. The Tapestri Platform is capable of identifying cancer cell mutation profiles. The Tapestri Platform’s ability to detect rare cancer subclones and co-occurring cancer mutations using single-cell genomics provides a precise way to measure therapy response and disease progression. Silver said the platform allows researchers to identify the mutations that are driving the disease and allows them to improve treatment.  “Cancer is far more complex than was initially anticipated. It’s not a single mutation, mutations evolve as the disease evolves,” Silver said. He noted that the disease can even evolve while a patient is undergoing treatment, which means there is an increased likelihood of additional therapy to address the latest mutation. It’s because of that ability that makes single cell analysis so important to the treatment, he said. Silver said it’s important for researchers and physicians to understand how the mutations work in the single cell that presents the disease. Since the launch of Mission Bio, Silver said they have been approached by researchers who have been seeking solutions that will allow them to target the individual genes that are key to their disease of focus. “Single-cell is the next frontier of genomics,” he said. Over the next year, Silver said he hopes to build on the key partnership with LabCorp in order to expand Mission Bio’s reach into precision medicine. “The partnership with LabCorp bridges across everything pharma needs to support the development of their pipeline,” Silver said. “This really fills out everything pharma needs to work with us as a technology provider.” Not only did Mission Bio forge a new collaboration with LabCorp, but the company also announced a partnership with Argonaut Manufacturing Services, a cGMP contract manufacturing organization, to serve as its preferred global CMO. Silver said the partnerships with the two companies its supply chain to provide customers with an end-to-end solution for its biopharmaceutical business and enables turnkey commercialization of its Tapestri Platform. Financial details of both deals were not disclosed. Over the remainder of the year, Silver said the company anticipates pushing into global markets through its partnership with LabCorp, which supports trials all over the world. He said the company will be pushing into Europe and Asia, with a particular focus on China, where there are numerous oncology trials taking place. “That’s a hungry and primed market for what we do,” he said of China. “I’m really excited about our expanding clinical business over the next year.”
总部位于旧金山的 Mission Bio 是唯一一家提供单细胞 DNA 测序的公司,该公司与 LabCorp 合作,利用该公司 Tapestri 平台的能力,提供更精确的临床试验。 总部位于北卡罗来纳州的 LabCorp 在美国拥有36个临床实验室网络。此外,作为交易的一部分, LabCorp 将评估 Tapestri 平台在临床诊断和开发新的配套诊断方面的应用。去年,该公司为 Mission Bio 的3000万美元 B 轮融资提供了支持。 Mission Bio 首席执行官查理•西尔弗( Charlie Silver )表示,与 LabCorp 的合作是他的公司扩大业务范围、让它们为客户提供更多服务的一种方式。Silver 在一次独家采访中告诉 BioSpace , LabCorp 使用 Tapestri 平台不仅将扩大 Mission Bio 与使用 LabCorp 的制药公司的接触,而且可能会导致这些制药公司对在临床试验过程中使用 Tapestri 平台的兴趣,以此作为改进它们的一种方式。西尔弗说,合作伙伴关系和他们的平台将帮助这些公司加速药物开发,特别是在癌症领域。 西尔弗说,多名癌症研究人员,特别是那些患有血癌的研究人员,已经转向使用 Tapestri 平台。自2017年推出该产品以来,血液肿瘤一直是公司关注的特定领域。西尔弗说,血癌基因组学已经被广泛理解,并且有更多的药物基于基因组学途径进入市场。西尔弗指出,美国食品药品监督管理局(Food and Drug Administration)正开始研究血液癌症的生物标志物,预计不久将发布一份新的指南草案。对生物标志物的关注可能会使 Mission Bio 受益,因为其单一的细胞分析平台。 Tapestri 平台能够识别癌症细胞突变剖面。Tapestri 平台能够使用单细胞基因组学检测罕见的癌症亚克隆和共同发生的癌症突变,为测量治疗反应和疾病进展提供了一种精确的方法。西尔弗说,该平台使研究人员能够识别驱动疾病的突变,并使他们能够改善治疗。 “癌症比最初预计的要复杂得多。它不是单一的突变,而是随着疾病的发展而发生的突变。” 他指出,这种疾病甚至可以在病人接受治疗的同时发展,这意味着有更多的可能性进行额外的治疗以解决最新的突变。他说,这是因为这种能力使得单细胞分析对治疗非常重要。西尔弗说,研究人员和医生必须了解这种突变是如何在单一细胞中起作用的,而这种细胞正是这种疾病的表现。西尔弗说,自从“使命生物”启动以来,一直在寻找解决方案的研究人员一直在与他们接触,这些解决方案将使他们能够针对对他们的注意力疾病至关重要的个体基因。 “单细胞是基因组学的下一个前沿领域,”他说。 在接下来的一年里,西尔弗表示,他希望与 LabCorp 建立关键的合作伙伴关系,以扩大 Mission Bio 在精准医疗领域的影响力。 “与 LabCorp 的合作跨越了制药公司需要支持的所有领域,”西尔弗表示。“这真的填补了制药公司作为技术提供商与我们合作所需的一切。” Mission Bio 不仅与 LabCorp 建立了新的合作关系,而且还宣布与 cGMP 合同制造组织 Argonaut Manufacturing Services 建立合作关系,作为其首选的全球 CMO 。 Silver 表示,与两家公司的供应链合作,为客户提供生物制药业务的端到端解决方案,并实现 Tapestri 平台的交钥匙商业化。两笔交易的财务细节均未披露。 西尔弗表示,在今年剩余时间里,该公司预计将通过与支持全球试验的 LabCorp 的合作,进军全球市场。他说,该公司将进军欧洲和亚洲,特别关注中国,那里正在进行大量的肿瘤试验。 他谈到中国时表示:“对于我们所做的事情来说,这是一个饥肠辘辘、充满活力的市场。”“我对我们未来一年扩大临床业务感到非常兴奋。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文